Adult IDH-wildtype glioblastoma in Mexico and Latin America: contemporary standards, emerging strategies, and an evidence-to-implementation roadmap

@article{camacho2026adult,
  title = {{Adult IDH-wildtype glioblastoma in Mexico and Latin America: contemporary standards, emerging strategies, and an evidence-to-implementation roadmap}},
  author = {Alejandro Rodríguez Camacho and Emmanuel Polito-Salazar and Ximena Blasco and Juan Carlos Romero-Valencia and Irving Fuentes-Calvo and Dharely Cid-Sánchez and José Guillermo Flores-Vázquez and Monica Serrano-Murillo and Bernardo Cacho-Díaz and Alipio González Vázquez and José Omar Santellán Hernández and Daniel Alejandro Vega Moreno and Enrique Caballé-Pérez and Daniel San-Juan and Emilio García-Gómez and Daniel Ballesteros-Herrera and Talia Wegman-Ostrosky and Oswaldo Alan Chávez Martínez and Efraín Isaías Camarin Sánchez and Raúl Mellado Orellana and Karen Elizabeth Padilla-Leal and Julia Moscardini-Martelli and Andrea Garcia-Bitar and Federico Maldonado Magos and Jorge Alejandro Torres-Ríos and Miguel Ángel Celis López and Guillermo Axayacalt Gutiérrez-Aceves and Sergio Moreno-Jiménez},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1998982},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1998982/full},
  note = {CC BY 4.0},
}

TY  - JOUR
TI  - Adult IDH-wildtype glioblastoma in Mexico and Latin America: contemporary standards, emerging strategies, and an evidence-to-implementation roadmap
AU  - Alejandro Rodríguez Camacho
AU  - Emmanuel Polito-Salazar
AU  - Ximena Blasco
AU  - Juan Carlos Romero-Valencia
AU  - Irving Fuentes-Calvo
AU  - Dharely Cid-Sánchez
AU  - José Guillermo Flores-Vázquez
AU  - Monica Serrano-Murillo
AU  - Bernardo Cacho-Díaz
AU  - Alipio González Vázquez
AU  - José Omar Santellán Hernández
AU  - Daniel Alejandro Vega Moreno
AU  - Enrique Caballé-Pérez
AU  - Daniel San-Juan
AU  - Emilio García-Gómez
AU  - Daniel Ballesteros-Herrera
AU  - Talia Wegman-Ostrosky
AU  - Oswaldo Alan Chávez Martínez
AU  - Efraín Isaías Camarin Sánchez
AU  - Raúl Mellado Orellana
AU  - Karen Elizabeth Padilla-Leal
AU  - Julia Moscardini-Martelli
AU  - Andrea Garcia-Bitar
AU  - Federico Maldonado Magos
AU  - Jorge Alejandro Torres-Ríos
AU  - Miguel Ángel Celis López
AU  - Guillermo Axayacalt Gutiérrez-Aceves
AU  - Sergio Moreno-Jiménez
PY  - 2026
DA  - 2026/10/28
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1998982
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1998982/full
AB  - Glioblastoma remains a major therapeutic challenge, and disparities in diagnostic capacity, treatment access, and continuity of care may further limit outcomes in Mexico and Latin America. This structured narrative review examines contemporary management of glioblastoma in adults, focusing on implementation of evidence-based care across resource-variable health systems. We reviewed literature published from 2005 through August 2026, including guidelines, consensus statements, randomized trials, prospective and registry-based studies, systematic reviews, meta-analyses, regional cohorts, epidemiological data, and health-system evidence. Current evidence supports integrated molecular diagnosis, maximal safe resection, postoperative radiotherapy with temozolomide, individualized management at recurrence, and early supportive and palliative care. Molecular classification and standardized imaging are essential to treatment selection and response assessment, whereas emerging targeted, immune, cellular, DNA-damage response, blood–brain barrier, and artificial intelligence approaches remain dependent on indication-specific evidence and appropriate clinical-trial or specialist oversight. Contemporary epidemiological and real-world studies provide external survival benchmarks, although differences in molecular classification, population selection, and study design limit direct comparisons with regional estimates and clinical-trial outcomes. Regional studies identify gaps in molecular testing, radiotherapy access, treatment continuity, and socioeconomic and geographic equity; however, evidence remains concentrated in a limited number of countries and tertiary centers, limiting its representativeness across Latin America. We propose a conceptual, resource-stratified, bidirectional local-to-hub framework in which routine care remains local when quality standards can be met, while specialist centers provide complex diagnostics, procedures, treatment review, recurrence assessment, and research access. Shared infrastructure for remote review, specimen and data transfer, patient navigation, and prospective quality measurement may reduce avoidable barriers without lowering clinical standards. The framework distinguishes established care from specialist-supported and investigational strategies and proposes indicators to evaluate diagnostic timeliness, treatment completion, referral performance, supportive care, equity, and research access. Improving outcomes requires not only access to effective therapies, but reliable systems capable of delivering them consistently and equitably throughout the course of disease.
SN  - 2234-943X
ER  -